> Belgium's UCB asked European regulators to approve its autoimmune-disorder med Cimzia for treatment of rheumatoid arthritis; it's already FDA-approved for use in Crohn's disease. Report
> Cipla received product patents in India for new forms of the blockbuster drugs Nexium, a heartburn treatment from AstraZeneca, and Fosamax, Merck's osteoporosis med. Report
> Sweden's Orexo got an approval recommendation from Europe's Committee for Medicinal Products for Human Use for Rapinyl, a drug for breakthrough cancer pain. Report
> Unilife Medical Solutions inked a five-year, $16.4 million global licensing agreement with Sanofi-Aventis for its ready-to-fill syringe product. Report
> China's vertically integrated Yongxin Pharmaceuticals signed a 10-year franchise deal with an unnamed U.S. drug chain to operate stores in Jilin Province. Report
> Eli Lilly will pay $64,400 to settle a lawsuit charging severance pay was withheld from a long-time employee ito force her to withdraw a discrimination charge. Report
> A new test that can detect multiple-drug-resistant tuberculosis in two days instead of the standard two to three months promises to help significantly improve treatment and prevent the spread of the airborne infection. Report
> A closely watched Alzheimer's drug being developed by H. Lundbeck and its U.S. partner Myriad Genetics failed a crucial late-stage study, sending shares of Lundbeck down to a four-year low and triggering a decision to axe the development program. Flurizan report
> ThromboGenics is touting data from a Phase IIb trial of microplasmin for vitreous injection, saying it resolved the underlying disease in close to a third of all patients in one dosage group without the need of a vitrectomy. ThromboGenics report
> ZymoGenetics has lined up $100 million in fresh financing from Deerfield Management. ZymoGenetics report
> The FDA has rejected Labopharm's appeal of the regulators' decision on once-daily tramadol, but kept the door open to an approval. Report
> The Wall Street Journal offers more bleak assessments from the pharma industry on their ability to win an FDA approval for a new therapy. Report
> Anyone looking for fresh signs of the faltering state of the U.K.'s biotech industry need look no further than Ardana. Unable to engineer a speedy refinancing, sale or merger, the Scottish developer--a specialist in reproductive health--brought in the administrators to run the company and suspended trading of its shares. Report
And Finally... Another reason to eat salmon: Low levels of "good" cholesterol are associated with poor memory, researchers found. Report